527 related articles for article (PubMed ID: 10930856)
41. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.
Buckley C; Hoffmann V; Shapiro J; Saari S; Cambazard F; Milsgaard M
Dermatology; 2008; 217(2):107-13. PubMed ID: 18463448
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
Kragballe K; Noerrelund KL; Lui H; Ortonne JP; Wozel G; Uurasmaa T; Fleming C; Estebaranz JL; Hanssen LI; Persson LM
Br J Dermatol; 2004 Jun; 150(6):1167-73. PubMed ID: 15214905
[TBL] [Abstract][Full Text] [Related]
43. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of acute episodes of atopic dermatitis. Double-blind comparative study with 0.05% halometasone cream versus 0.25% prednicarbate cream].
Ulrich R; Andresen I
Fortschr Med; 1991 Dec; 109(36):741-4. PubMed ID: 1778534
[TBL] [Abstract][Full Text] [Related]
45. A controlled clinical trial of a new formulation of betamethasone dipropionate cream in once-daily treatment of psoriasis.
Ellis CN; Katz HI; Rex IH; Shavin JS; Van Scott EJ; VanderPloeg D
Clin Ther; 1989; 11(6):768-74. PubMed ID: 2692821
[TBL] [Abstract][Full Text] [Related]
46. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
van de Kerkhof PC; Hoffmann V; Anstey A; Barnes L; Bolduc C; Reich K; Saari S; Segaert S; Vaillant L
Br J Dermatol; 2009 Jan; 160(1):170-6. PubMed ID: 19067709
[TBL] [Abstract][Full Text] [Related]
47. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.
Yentzer BA; Camacho FT; Young T; Fountain JM; Clark AR; Feldman SR
J Drugs Dermatol; 2010 Apr; 9(4):324-9. PubMed ID: 20514788
[TBL] [Abstract][Full Text] [Related]
48. A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema.
Delescluse J; van der Endt JD
Cutis; 1996 Feb; 57(2 Suppl):32-8. PubMed ID: 8646867
[TBL] [Abstract][Full Text] [Related]
49. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis.
De Belilovsky C; Roo-Rodriguez E; Baudouin C; Menu F; Chadoutaud B; Msika P
J Dermatolog Treat; 2011 Dec; 22(6):359-65. PubMed ID: 20964572
[TBL] [Abstract][Full Text] [Related]
50. Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation.
Boner AL; Richelli C; De Stefano G; Valletta EA; Ferrari S; Mengoni M
Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):118-20. PubMed ID: 2985514
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.
Siegfried E; Korman N; Molina C; Kianifard F; Abrams K
J Dermatolog Treat; 2006; 17(3):143-50. PubMed ID: 16854753
[TBL] [Abstract][Full Text] [Related]
52. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children.
Lassus A
Int J Dermatol; 1984 Oct; 23(8):565-6. PubMed ID: 6389385
[TBL] [Abstract][Full Text] [Related]
53. Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis.
Parneix-Spake A; Goustas P; Green R
J Dermatolog Treat; 2001 Dec; 12(4):191-7. PubMed ID: 12241627
[TBL] [Abstract][Full Text] [Related]
54. Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis.
Kaplan RJ; Daman L; Rosenberg EW; Feigenbaum S
Arch Dermatol; 1978 Jan; 114(1):60-2. PubMed ID: 339846
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
[TBL] [Abstract][Full Text] [Related]
56. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.
Papp K; Staab D; Harper J; Potter P; Puig L; Ortonne JP; Molloy S; Barbier N; Paul C;
Int J Dermatol; 2004 Dec; 43(12):978-83. PubMed ID: 15569038
[TBL] [Abstract][Full Text] [Related]
57. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.
Lotti T; Buggiani G; Troiano M; Assad GB; Delescluse J; De Giorgi V; Hercogova J
Dermatol Ther; 2008 Jul; 21 Suppl 1():S20-6. PubMed ID: 18727812
[TBL] [Abstract][Full Text] [Related]
58. Effect on plasma cortisol level and urinary cortisol excretion, in healthy volunteers, after application of three different topical steroid ointments under occlusion.
Scott M; Malmsten LA; Thelin I
Acta Derm Venereol; 1981; 61(6):543-6. PubMed ID: 6177167
[TBL] [Abstract][Full Text] [Related]
59. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
[TBL] [Abstract][Full Text] [Related]
60. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
